A detailed history of Northern Trust Corp transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 75,567 shares of KRON stock, worth $73,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,567
Previous 75,627 0.08%
Holding current value
$73,299
Previous $98,000 5.1%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.73 - $1.38 $43 - $82
-60 Reduced 0.08%
75,567 $93,000
Q1 2024

May 14, 2024

SELL
$1.02 - $1.3 $17,386 - $22,159
-17,046 Reduced 18.39%
75,627 $98,000
Q3 2023

Nov 13, 2023

SELL
$1.23 - $2.25 $1,164 - $2,130
-947 Reduced 1.01%
92,673 $120,000
Q2 2023

Aug 11, 2023

SELL
$1.24 - $1.92 $318,737 - $493,528
-257,046 Reduced 73.3%
93,620 $161,000
Q1 2023

May 15, 2023

BUY
$1.34 - $2.62 $4,401 - $8,606
3,285 Added 0.95%
350,666 $511,000
Q4 2022

Feb 13, 2023

SELL
$1.44 - $3.44 $9,329 - $22,287
-6,479 Reduced 1.83%
347,381 $562,000
Q3 2022

Nov 14, 2022

SELL
$3.35 - $5.55 $6,633 - $10,989
-1,980 Reduced 0.56%
353,860 $1.19 Million
Q2 2022

Aug 12, 2022

SELL
$3.12 - $7.52 $10,420 - $25,116
-3,340 Reduced 0.93%
355,840 $1.3 Million
Q1 2022

May 13, 2022

SELL
$6.26 - $14.42 $121,181 - $279,142
-19,358 Reduced 5.11%
359,180 $2.6 Million
Q4 2021

Feb 08, 2022

BUY
$11.35 - $21.18 $296,870 - $553,984
26,156 Added 7.42%
378,538 $5.14 Million
Q3 2021

Nov 15, 2021

BUY
$18.17 - $24.7 $487,192 - $662,281
26,813 Added 8.24%
352,382 $7.39 Million
Q2 2021

Aug 13, 2021

BUY
$20.08 - $29.02 $3.28 Million - $4.74 Million
163,311 Added 100.65%
325,569 $7.8 Million
Q1 2021

May 12, 2021

SELL
$27.0 - $32.48 $204,363 - $245,841
-7,569 Reduced 4.46%
162,258 $4.75 Million
Q4 2020

Feb 11, 2021

BUY
$26.68 - $38.23 $4.53 Million - $6.49 Million
169,827 New
169,827 $5.07 Million

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $55.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.